article Open AccessTop 1% cited
Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer
JNCI Journal of the National Cancer Institute · 2003 · Vol. 95(12) · pp. 868–878
Gerrit Draisma✉(Erasmus MC)Rob BoerSuzie J. OttoIngrid W van der CruijsenRonald DamhuisF.H. SchröderHarry J. de Koning
Abstract
These model-based lead-time estimates support a prostate cancer screening interval of more than 1 year.
Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchColorectal Cancer Screening and DetectionMedicineProstate cancerProstate cancer screeningConfidence intervalProstateRelative riskCancerProstate-specific antigenIncidence (geometry)Gynecology
MeSH terms
AgedEuropeHumansMaleMass ScreeningMiddle AgedModels, BiologicalNetherlandsProstatic NeoplasmsTime FactorsProstate-Specific Antigen
Citations
1,073
FWCI
41.30
field-weighted impact
References
38
Percentile
100%
vs. same field & year
Citations per year
Cited by
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clinical Chemistry · 2008 · 1,130 citations
Screening for prostate cancer
Cochrane Database of Systematic Reviews · 2013 · 1,144 citations
Early Detection of Prostate Cancer: AUA Guideline
The Journal of Urology · 2013 · 1,247 citations
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine · 2012 · 2,517 citations
Overdiagnosis and Overtreatment of Prostate Cancer
European Urology · 2014 · 939 citations
Overdiagnosis in Cancer
JNCI Journal of the National Cancer Institute · 2010 · 1,567 citations
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
European Urology · 2019 · 676 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.